Post Profile

Ibrutinib in CLL: Added benefit for treatment-naive patients not proven

(Institute for Quality and Efficiency in Health Care) The dossier contained no suitable data for any of the three subgroups of treatment-naive patients with chronic lymphocytic leukaemia, for whom the drug was newly approved in 2016...
read more


Related Posts

Older People With Chronic Leukemia May Benefit From Experimental Agent

Health : Medical News Today

The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial. The phase I/II trial, co-led by rese...

Idelalisib in second-line treatment for CLL: Added benefit again not proven

Academics / General Science : Science Codex

Already in 2014, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined in an early benefit assessment whether idelalisib offers advantages over the appropriate comparator therapy for patients with chronic l...

MabThera Approved In The EU For Patients With Chronic Lymphocytic Leukaemia

Health : Medical News Today

Roche announced that the European Commission has approved MabThera (rituximab) in combination with chemotherapy for use in patients with previously-untreated chronic lymphocytic leukaemia (CLL), the most common type of leukaemia to ...

Ibrutinib: Indication of added benefit in one of three therapeutic indications

Academics / General Science : ScienceDaily: Science Society

No added benefit has been proven for chronic lymphocytic leukaemia and Waldenström macroglobulinaemia. Certain patients with relapsed or refractory mantle cell lymphoma benefit from the drug.

FDA approves Imbruvica to treat chronic lymphocytic leukemia

Health : Medical News Today

The U.S. Food and Drug Administration has expanded the approved use of Imbruvica (ibrutinib) for chronic lymphocytic leukemia (CLL) patients who have received at least one previous therapy.CLL is a rare blood and bone marrow disease...


Copyright © 2016 Regator, LLC